Who
Jingrong Jean Cui
President and CEO
Company insider
Files Form 4 as: President and CEO, BlossomHill Therapeutics; Chief Scientific Officer, Turning Point Therapeutics.
In numbers
- Trades disclosed
- 202
- Buys
- 0
- Sells
- 52
- Bought
- $0
- Sold
- $40.5M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 27 Jun 2019
- Last trade
- 10 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,600,682 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Code C | —113,435 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Code C | —124,779 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,600,682 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —113,435 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —124,779 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,600,682 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —113,435 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —124,779 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,600,682 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Code C | —113,435 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Code C | —124,779 | filing |
| 6 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —676,205 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —676,205 at $0.00 | filing |
| 9 Jun 2020filed 10 Jun 2020 | Turning Point Therapeutics | SEC FORM 4 Sold | $26K412 at $63.80 | filing |
| 9 Jun 2020filed 10 Jun 2020 | Turning Point Therapeutics | SEC FORM 4 Sold | $109K1,688 at $64.82 | filing |
| 9 Jun 2020filed 10 Jun 2020 | Turning Point Therapeutics | SEC FORM 4 Sold | $297K4,515 at $65.80 | filing |
| 9 Jun 2020filed 10 Jun 2020 | Turning Point Therapeutics | SEC FORM 4 Sold | $172K2,585 at $66.60 | filing |
| 9 Jun 2020filed 10 Jun 2020 | Turning Point Therapeutics | SEC FORM 4 Sold | $20K300 at $67.48 | filing |
| 8 Jun 2020filed 8 Jun 2020 | Turning Point Therapeutics | SEC FORM 4 Sold | $117K1,872 at $62.50 | filing |
News
No headline names them, or the companies they trade most, lately.